Please assess the completion status of the following clinical trial:

Trial Title: SALT-2 Trial Study of Ascending Levels of Tolvaptan in Hyponatremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Hyponatremia in euvolemic or hypervolemic states, defined as serum sodium \<135 mEq/L prior to randomization.~2. Able to give Informed Consent~Exclusion Criteria:~1. Women who are breast feeding and females of childbearing potential who are not using acceptable contraceptive methods~2. Hyponatremia in hypovolemic states.~3. Acute and transient hyponatremia associated with head trauma or post-operative state.~4. Hyponatremia due to uncontrolled hypothyroidism or uncontrolled adrenal insufficiency.~5. Cardiac surgery within 30 days of potential study enrollment, excluding percutaneous coronary interventions.~6. History of a myocardial infarction within 30 days of potential study enrollment.~7. History of sustained ventricular tachycardia or ventricular fibrillation within 30 days, unless in the presence of an automatic implantable cardioverter defibrillator.~8. Severe angina including angina at rest or at slight exertion and/or unstable angina.~9. History of a cerebrovascular accident within the last 30 days.~10. Subjects with psychogenic polydipsia may not be included, however subjects with other psychiatric illness may be included.~11. Systolic arterial blood pressure \<90 mmHg.~12. History of hypersensitivity and/or idiosyncratic reaction to benzazepine or benzazepine derivatives (such as benazepril.).~13. History of drug or medication abuse within the past year,or current alcohol abuse.~14. Uncontrolled diabetes mellitus defined as fasting glucose \>300mg/dL.~15. Urinary tract obstruction except BPH if non-obstructive.~16. Previous participation in another clinical drug trial within the past 30 days.~17. Previous participation in this or any other tolvaptan clinical trial.~18. Terminally ill or moribund condition with little chance of short term survival.~19. Serum creatinine \>3.5 mg/dL.~20. Serum sodium \<120 mEq/L with associated neurologic impairment, i.e. symptoms such as apathy, confusion, seizures.~21. Patients with progressive or episodic neurologic disease such as multiple sclerosis or history of multiple strokes.~22. Child-Pugh score greater than 10 (unless approved)~23. Patients receiving intravenous fluids at a rate greater than KVO (Keep Vein Open).~24. Hyponatremia due to lab artifacts~25. Patients receiving AVP or its analogs for treatment of any condition.~26. Patients receiving within 7 days of randomization, other medications for treatment of hyponatremia specifically: demeclocycline, lithium carbonate or urea~27. Patients likely requiring IV saline for correction of symptomatic or asymptomatic severe hyponatremia during the course of the study.~28. Severe pulmonary artery hypertension~29. Hyponatremia should not be the result of any medication that can safely be withdrawn

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).